AbbVie
Why trials sponsored by AbbVie stopped, in this sample of ClinicalTrials.gov.
21 stopped trials with a clear reason; 81% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 16 | 76% |
| safety | 2 | 10% |
| other | 1 | 5% |
| futility | 1 | 5% |
| slow accrual | 1 | 5% |
Where it ranks
- #1 of 90 sponsors by share of trials stopped for: funding or business decisions (76%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique
NCT05606757 · WITHDRAWN · funding business
“Strategic considerations” - A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958 · TERMINATED · funding business
“Strategic considerations” - A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
NCT06362031 · WITHDRAWN · funding business
“Strategic considerations” - A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT05513703 · TERMINATED · funding business
“Strategic considerations” - A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
NCT03400306 · WITHDRAWN · funding business
“Strategic considerations” - A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
NCT05026502 · TERMINATED · funding business
“Strategic considerations” - Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
NCT04912063 · TERMINATED · funding business
“Strategic considerations” - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
NCT04888585 · TERMINATED · funding business
“Business decision” - Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
NCT04403763 · TERMINATED · funding business
“Strategic considerations” - A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
NCT04272203 · TERMINATED · funding business
“Strategic considerations” - A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
NCT04127695 · WITHDRAWN · funding business
“Strategic considerations” - A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
NCT03659669 · SUSPENDED · funding business
“Strategic considerations” - Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
NCT02786563 · WITHDRAWN · funding business
“Strategic considerations” - UNITE Study: Understanding New Interventions With GBM ThErapy
NCT03419403 · TERMINATED · futility
“The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.” - A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
NCT03145909 · TERMINATED · safety
“Safety” - Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
NCT03148756 · TERMINATED · funding business
“Study stopped due to business reasons.” - A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
NCT03026166 · TERMINATED · safety
“Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.” - Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
NCT02806362 · WITHDRAWN · other
“Study halted prematurely, prior to enrollment of first participant” - Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
NCT02322723 · WITHDRAWN · slow accrual
“No enrollment” - Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
NCT02203773 · TERMINATED · funding business
“Strategic considerations” - An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
NCT02082197 · WITHDRAWN · funding business
“Other - not a safety issue”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.